NMOSD with anti-MOG antibodies following anti-TNFα therapy: A case report

[en] Tumor necrosis factor α (TNFα) inhibitors are highly effective and a therapeutic choice for several inflammatory diseases. Their broad and long-term use is associated with a growing number of paradoxical autoimmune events including demyelinating lesions of the central nervous system (CNS). We report and discuss a case of neuromyelitis optica spectrum disorder (NMOSD) with positive myelin oligodendrocyte glycoprotein antibodies (MOG-IgG1) following anti-TNFα therapy for a pustular psoriasis.

Disciplines :

Neurology

Author, co-author :

LOMMERS, Emilie ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de neurologie

DEPIERREUX, Frédérique ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de neurologie

HANSEN, Isabelle ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Unité de neuro immunologie clinique

DIVE, Dominique ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Unité de revalidation neurologique (Esneux)

MAQUET, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de neurologie

Language :

English

Title :

NMOSD with anti-MOG antibodies following anti-TNFα therapy: A case report

Publication date :

November 2018

Journal title :

Multiple Sclerosis and Related Disorders

ISSN :

2211-0348

eISSN :

2211-0356

Publisher :

Elsevier, Netherlands

Volume :

Pages :

37-39

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://authors.elsevier.com/a/1XjPy7skoexbI6

Available on ORBi :

since 18 September 2018

Statistics

Number of views

180 (14 by ULiège)

Number of downloads

245 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Fromont, A., Seze, J.D., Fleury, M.C., Maillefert, J.F., Moreau, T., Inflammatory demyelinating events following treatment with anti-tumor necrosis factor (2009) Cytokine, 45, pp. 55-57
Jarius, S., Ruprecht, K., Kleiter, I., Borisow, N., Asgari, N., Pitarokoili, K., Pache, F., Wildemann, B., MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome (2016) J. Neuroinflamm., 13, pp. 1-45
Jurynczyk, M., Messina, S., Woodhall, M.R., Raza, N., Everett, R., Roca-Fernandez, A., Tackley, G., Palace, J., Clinical presentation and prognosis in MOG-antibody disease: A UK study (2017) Brain, 140, pp. 3128-3138
Probert, L., TNF and its receptors in the CNS: the essential, the desirable and the deleterious effects (2015) Neuroscience, 302, pp. 2-22
Ramanathan, S., Dale, R.C., Brilot, F., Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination (2016) Autoimmun. Rev., 15, pp. 307-324
Retamozo, S., Ramos-Casals, M., Pérez De Lis, M., Flores-Chavez, A., Arteaga, S., Galcerán-Chaves, C., Kostov, B., Brito-Zerón, P., Pharmacovigilance surveillance of autoimmune diseases induced by biological agents: a review of 12013 cases (aebiogeas-semi registry) (2017) Arthritis Rheumatol., 69, pp. 1255-1271
TNF neutralization in MS: results of a randomized, placebo- controlled multicenter study (1999) Neurology, 53, pp. 457-465
Waters, P., Woodhall, M., O'Connor, K.C., Reindl, M., Lang, B., Sato, D.K., Jurynczyk, M., Vincent, A., MOG cell-based assay detects non-MS patients with inflammatory neurologic disease (2015) Neurol. Neuroimmunol. NeuroInflamm., 2, p. e89
Wingerchuk, D.M., Banwell, B., Bennett, J.L., Cabre, P., Carroll, W., Chitnis, T., de Seze, J., Weinshenker, B.G., International Panel for NMO Diagnosis, International Consensus Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorders (2015) Neurology, 852, pp. 177-189